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Objectives: Untreated hepatitis C virus (HCV) infection results in chronic liver 
disease. The prevalence in The Netherlands is estimated at 0.1-0.4% with 50% of 
patients having HCV genotype 1 (GT1). Sofosbuvir (SOF), a novel Direct Antiviral 
Agent (DAA), reached high rates of sustained virological response (SVR) when 
given with pegylated interferon-α and ribavirin (PegIFN-α /RBV) in chronic HCV (all 
genotypes). This study compares the costs per successfully treated patient with 
sofosbuvir compared to current standard of care (SoC) in the Netherlands in treat-
ment-naïve GT1 patients. MethOds: A Markov transition cost-utility model was 
used, reflecting efficacy and safety data from published RCTs with SOF+PegIFN- 
α /RBV, PegIFN-α /RBV, telaprevir (TVR) +PegIFN-α /RBV and boceprevir (BOC) 
+PegIFN-α /RBV. Medical resource use is based on clinical guidelines and expert 
opinion. Costs include treatment costs, monitoring costs, costs for treatment of 
complications and adverse events. The model has a lifetime horizon and costs 
are discounted with 4% and outcomes with 1.5%. Successfully treated patients 
are defined as having an SVR. Results are presented for a treatment-naïve GT1 
population. Results: The SVR rate for SOF ranged from 91.7% in non-cirrhotic 
patients to 80.1% in cirrhotic patients. This was 43.6% and 23.6% for PegIFN-α , 75.4% 
and 61.9% in TVR and 64.1% and 55% for BOC. Total treatment costs ranged from 
€ 55,376 to € 70,336 for SOF (non-cirrhotic and cirrhotic), € 22,240 and € 44,751 for 
PegIFN-α , € 42,593 to € 60,071 for TVR and € 39,634 to € 57,647 for BOC. The costs per 
SVR varied from € 60.388 to € 87,050 for SOF (non-cirrhotic and cirrhotic), € 51,009 
to € 189,623 for PegIFN-α , € 56,489 to € 97,045 for TVR and € 61,832 to € 104,813 for 
BOC. cOnclusiOns: The costs per successfully treated patient with sofosbuvir are 
comparable to current standard of care in GT1 treatment naive patients without 
cirrhosis and are lower than SoC in cirrhotic patients in The Netherlands.
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Objectives: Typically, healthy adults are not targeted for influenza vaccination, 
leading to out-of-pocket expenses if they choose to be vaccinated. This can be a 
deterrent to vaccination coupled with a low concern for consequences of infec-
tion. However, despite a lower attack and complication rate than other age/risk 
groups, infection in healthy employees can result in important loss of productivity 
to employers. We estimated the benefits of vaccinating healthy employees with 
a quadrivalent inactivated influenza vaccine (QIV). MethOds: A decision tree 
model was developed to evaluate an annual employer-paid vaccination program 
for working adults in the UK versus no vaccination. Probabilities and costs were 
from peer-reviewed literature and government reports. A population of 5,000 
healthy employees, a 75% vaccination coverage and an average daily productivity 
of two times the average UK wage were assumed. Vaccine efficacy estimates were 
based on systematic reviews/meta-analyses and a 10-year history of match/mis-
match. Sensitivity analysis of uncertainty was conducted. Results: The model 
estimated that vaccination with QIV would avert 159 cases of influenza, and 
1,066 days of absenteeism, resulting in a productivity loss of £134,007 annually. 
Considering the vaccine and administration costs (£57,675) the employer would 
save £76,332. The results are highly sensitive to the number of days an employee is 
absent due to a simple infection (no hospitalisation), the attack rate, and average 
productivity. In scenario analysis if the average productivity is set simply to the 
average wage, the employer would still save £9,328. cOnclusiOns: Vaccination 
campaigns paid for by an employer are estimated to be cost saving when infection 
results in at least 1.7 days of absenteeism for each case. A higher mortality rate 
(due to a more virulent strain, and/or inclusion of at risk adults) would introduce 
replacement costs, thereby raising the cost saving to the employer if they under-
took a vaccination program.
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Objectives: Fidaxomicin is the first in a new class of macrocylic antibiotics, 
indicated for the treatment of adults with Clostridium difficile infection (CDI) also 
known as C. difficile-associated diarrhoea (CDAD). Two phase III comparative clinical 
studies showed that fidaxomicin was non-inferior to vancomycin for clinical cure, 
and superior for recurrence and sustained clinical cure. The study objective was to 
perform a cost-effectiveness analysis of fidaxomicin for the treatment of severe 
CDI and the first severe recurrence compared to oral vancomycin from a Swedish 
health care perspective. MethOds: A Markov model was developed to analyse 
the cost-effectiveness of fidaxomicin compared to vancomycin in the treatment of 
patients with severe CDI, and patients with initial severe CDI recurrences, respec-
tively. The patient enters the model in the CDI health state and is treated either 
with fidaxomicin or vancomycin. Each treatment cycle was 10 days and the total 
time horizon was one-year. Deterministic and probabilistic sensitivity analyses 
were performed. Health state utilities were derived from the literature. Results: 
Fidaxomicin was associated with an increased cost per patient in the severe CDI 
population and was cost-saving in severe recurrent CDI patients. A utility gain was 
demonstrated in both fidaxomicin patient populations. The ICER was SEK 83,159 
per QALY for severe CDI and dominant for patients with a severe CDI recurrence 
(ICER = SEK -92,738 per QALY). Sensitivity analyses found the results to be robust. 
(1 EURO = 9.07 SEK). cOnclusiOns: Fidaxomicin was cost-effective in severe CDI 
Objectives: Although the real-time PCR-based assay SeptiFast® has proven 
its utility in different clinical settings, limited data are still available on its eco-
nomic performance. An Italian two-center observational study was conducted on 
hematological patients with signs of SIRS-SS (Systemic Inflammatory Response 
Syndrome with Suspected Sepsis) in order to partially fill this information 
gap. MethOds: 138 retrospective cases of SIRS-SS managed by classical diag-
nostic procedure are compared to prospectively collected data of 137 episodes 
managed with the addition of PCR assay. Events were paired through propensity-
score matching (PSM), based on a set of covariates identified by a backward selec-
tion algorithm, under two levels of tolerance for score difference: standard caliper 
(1) and a more restrictive threshold (0.05). SIRS-SS related mortality represents 
the primary clinical outcome; as secondary outcome, average LOSE (Length Of 
SIRS Episode) is considered. Costs, including diagnostic assays and pharmaceu-
tical charges, were recorded and compared between cohorts. Results: A total 
of 101 pairs of highly matched SIRS-SS episodes have been formed. Prospective 
cohort shows a non-significant trend to a lower mortality (8.24% vs. 13.48%). Under 
more stringent matching condition (77 pairs), episodes experienced by prospective 
patients are associated to a significantly lower mortality (3.13% vs 14.71%). No 
significant differences in the average LOSE are recorded. Traditional diagnostic 
assays cost is € 152 lower in the prospective cohor; however, this saving is com-
pletely offset by the cost of the PCR assay. The greatest saving related to the use 
of PCR assay is linked to the hard reduction in the empirical therapy (€ 488.44 per 
episode), main driver of the overall saving (€ 430.73 per episode), which results 
statistically significant. cOnclusiOns: These findings suggest that the routine 
use of combined traditional and PCR diagnostic assays may conduct to an early 
saving of broad-spectrum antibiotics, money, and health.
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Objectives: Human papillomavirus (HPV) vaccines offer primary prevention 
of HPV-related pre-cancers and cancers. AS04-adjuvanted HPV-16/18 vaccine 
(AS04v) has shown high efficacy (efficacy irrespective of the HPV type) in cervi-
cal high grade lesions (CIN2+, CIN3+). The objective of this study is to estimate 
overall impact on cervical cancer (CC) burden expected from AS04v in the Iberian 
Peninsula (Spain and Portugal). MethOds: Potential decline in CC cases resulting 
from women vaccination with AS04v was estimated using a previously published 
model. Model outcomes considered were estimated based on number of CC cases 
avoided associated with HPV specific CC incidence (HPV-16/18 cases and irrespec-
tive of HPV type). Vaccine effectiveness (VE, end-of-study analysis HPV-008 trial) 
against HPV-16/18 was set at 100% weighted with HPV-16/18 incidence reported in 
CC in Spain & Portugal. VE irrespective of HPV type was set at 93%. Vaccination cov-
erage was varied from 0% to 100%. Incremental number of cases avoided HPV-16/18 
related and irrespective of HPV type were calculated. Potential costs avoided were 
also estimated based on published lifetime CC costs. Results: Through vaccina-
tion considering VE irrespective of type and 70% vaccination coverage, AS04v could 
avoid an additional 206 CC cases in Portugal and 626 CC cases in Spain compared 
with 412 and 1.009 cases, respectively, due to 16/18 HPV types. VE against non-
vaccine types increased the estimated potential number of CC cases prevented by 
33% and 38% in Portugal and Spain, respectively. Associated cost avoided due to 
reduced CC treatment could reach 1.536.644€ in Portugal and 6.374.865€ in Spain 
(33% and 38% due to overall efficacy respectively). Cases avoided may increase 
linearly with increasing vaccination coverage. cOnclusiOns: HPV vaccination 
could considerably contribute to reducing the burden of cervical cancer in Spain 
and Portugal. AS04v offers potential broad protection and could maximize disease 
burden reduction due to non-vaccine type VE.
PIN54
Cost-effeCtIveNess aNalysIs of doluteGravIr for hIv PatIeNts IN 
sloveNIa
Hren R.1, Refoios Camejo R.2
1GlaxoSmithKline d.o.o., družba za promet s farmacevtskimi izdelki, Ljubljana, Slovenia,, 
2GlaxoSmithKline, Brentford, UK
Objectives: To analyze cost effectiveness of dolutegravir when compared to ralte-
gravir in both treatment-naïve (TN) and treatment-experienced (TE) patients in 
Slovenia. MethOds: We adapted ARAMIS-DTG, a published micro-simulation 
decision model, to the real-life conditions in Slovenia by using locally-specific pop-
ulation data and treatment costs of HIV patients, who are currently predominantly 
receiving first-line treatment. In the model, individual patients were followed 
throughout their lifetime and transitioned through mutually exclusive health 
states with the probability of disease progression being continuously adjusted on 
individual patient characteristics and the occurrence of events such as virological 
failure, opportunistic infections and/or adverse events. We compared dolutegravir 
and raltegravir under a »price parity« scenario. Results: Our model has shown 
that more than 90% of life-time treatment costs of HIV patients in Slovenia were 
due to anti-retroviral drugs. Survival curves and CD4+ cell count indicated that 
treatment with dolutegravir was more effective than treatment with raltegravir in 
both TN and TE HIV patients. In TN patients, dolutegravir also reduced costs and 
thus dominated raltegravir (saved € 1,608 and gained 0.092 QALYs - discounted at a 
rate of 3.5%). In TE patients, the resulting ICER was € 23,382 per QALY with the cost 
increase being associated with an expected greater survival of patients treated 
with dolutegravir. When accounting for that factor then also in the TE group, 
dolutegravir dominated raltegravir. The sensitivity analysis showed robustness of 
findings in both groups of patients. cOnclusiOns: Results of our study indicate 
that the introduction of new integrase inhibitor dolutegravir in Slovenia would 
not only reduce the costs but also improve health outcomes of HIV treatment in 
both TN and TE patients.
